Skip to main content

Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse.

  • 2017-04-26
  • Beneficial Microbes 8(2)
    • Christiane Danilo
    • E. Constantopoulos
    • Laurel A. K. McKee
    • Hao Chen
    • Jessica A. Regan
    • Yulia Lipovka
    • S. Lahtinen
    • Lotta Stenman
    • Thuy-Vi V. Nguyen
    • Kristian P. Doyle
    • Marvin J. Slepian
    • Zain I Khalpey
    • J. Konhilas

Abstract

There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.

Keywords: B. animalis ssp. lactis; cardiovascular disease; inflammation; probiotics; regulatory T cells.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactis B420Increased Anti-Inflammatory Cytokine LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced Cardiac InjuryBeneficial
Moderate
Bifidobacterium animalis subsp. lactis B420Reduced Inflammatory ResponseBeneficial
Moderate
Bifidobacterium lactis B420Mitigated Cardiac Injury from Myocardial InfarctionBeneficial
Large
Bifidobacterium lactis B420Reduced Inflammatory MarkersBeneficial
Moderate
Bifidobacterium lactis B420Reduced Inflammatory ResponseBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.